DE60239042D1 - Haptene, Immunogene, Antikörper und Konjugate für 2-oxo-3-hydroxy LSD - Google Patents

Haptene, Immunogene, Antikörper und Konjugate für 2-oxo-3-hydroxy LSD

Info

Publication number
DE60239042D1
DE60239042D1 DE60239042T DE60239042T DE60239042D1 DE 60239042 D1 DE60239042 D1 DE 60239042D1 DE 60239042 T DE60239042 T DE 60239042T DE 60239042 T DE60239042 T DE 60239042T DE 60239042 D1 DE60239042 D1 DE 60239042D1
Authority
DE
Germany
Prior art keywords
lsd
oxo
present
hydroxy
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60239042T
Other languages
English (en)
Inventor
Robert Ivan Mcconnell
El Ouard Benchikh
Stephen Peter Fitzgerald
John Victor Lamont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Randox Laboratories Ltd
Original Assignee
Randox Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Randox Laboratories Ltd filed Critical Randox Laboratories Ltd
Application granted granted Critical
Publication of DE60239042D1 publication Critical patent/DE60239042D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/946—CNS-stimulants, e.g. cocaine, amphetamines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/814—Pregnancy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60239042T 2001-12-20 2002-12-17 Haptene, Immunogene, Antikörper und Konjugate für 2-oxo-3-hydroxy LSD Expired - Lifetime DE60239042D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01205057 2001-12-20

Publications (1)

Publication Number Publication Date
DE60239042D1 true DE60239042D1 (de) 2011-03-10

Family

ID=27589058

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60239042T Expired - Lifetime DE60239042D1 (de) 2001-12-20 2002-12-17 Haptene, Immunogene, Antikörper und Konjugate für 2-oxo-3-hydroxy LSD

Country Status (6)

Country Link
US (1) US7115718B2 (de)
EP (1) EP1321466B1 (de)
CN (1) CN1300139C (de)
AT (1) ATE496917T1 (de)
DE (1) DE60239042D1 (de)
ES (1) ES2361907T3 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794496B2 (en) * 2000-04-07 2004-09-21 Roche Diagnostics Corporation Immunoassay for LSD and 2-oxo-3-hydroxy-LSD
JP4696079B2 (ja) 2003-12-17 2011-06-08 ヤンセン アルツハイマー イミュノセラピー Ａβ免疫原性ペプチド担体結合物およびそれの製造方法
US20060223998A1 (en) * 2005-03-30 2006-10-05 Fang-Jie Zhang Synthetic LSD metabolite for preparing haptens used in an LSD metabolite immunoassay
WO2007097065A1 (ja) * 2006-02-23 2007-08-30 Japan Science And Technology Agency ハプテン化合物および抗体
CN102707047A (zh) * 2012-06-05 2012-10-03 南通市产品质量监督检验所 快速检测麦角生物碱的胶体金检测卡及其制备方法
CN102707046A (zh) * 2012-07-13 2012-10-03 江苏省苏微微生物研究有限公司 一种麦角生物碱多残留分析的酶联免疫分析测试盒及其检测方法
GB201217938D0 (en) * 2012-10-08 2012-11-21 Randox Lab Ltd Immunoassays for meperidine and metabolites
BR112019026434A2 (pt) 2017-06-14 2020-07-14 Virometix Ag peptídeos cíclicos para proteção contra vírus sincicial respiratório
CA3121724A1 (en) 2018-12-20 2020-06-25 Virometix Ag Lipopeptide building blocks and synthetic virus-like particles
CN110187094A (zh) * 2019-06-27 2019-08-30 贵州盛世康生物科技有限公司 一种5－羟基吲哚乙酸测定试剂
IL312785A (en) 2020-05-19 2024-07-01 Cybin Irl Ltd Denatured Tryptamine Derivatives and Methods of Use
US20230355737A1 (en) 2020-09-28 2023-11-09 Dbv Technologies Particle comprising an rsv-f protein for use in rsv vaccination
CN112924665B (zh) * 2021-02-19 2023-10-03 山东莱博生物科技有限公司 一种抗体辣根过氧化物酶标记物及其制备与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207396B1 (en) * 1995-11-20 2001-03-27 Microgenics Corporation Immunoassay reagents and methods for determination of LSD and LSD metabolites
US6063908A (en) * 1996-07-02 2000-05-16 Roche Diagnostics Corporation Reagents for lysergic acid diethylamide immunoassay
US6306616B1 (en) * 1998-03-27 2001-10-23 Microgenics Corporation Adsorption type confirmatory assays
US6794496B2 (en) * 2000-04-07 2004-09-21 Roche Diagnostics Corporation Immunoassay for LSD and 2-oxo-3-hydroxy-LSD

Also Published As

Publication number Publication date
EP1321466A1 (de) 2003-06-25
ATE496917T1 (de) 2011-02-15
CN1300139C (zh) 2007-02-14
US7115718B2 (en) 2006-10-03
US20030143655A1 (en) 2003-07-31
CN1450065A (zh) 2003-10-22
ES2361907T3 (es) 2011-06-24
EP1321466B1 (de) 2011-01-26

Similar Documents

Publication Publication Date Title
ATE496917T1 (de) Haptene, immunogene, antikörper und konjugate für 2-oxo-3-hydroxy lsd
ATE492565T1 (de) Immunogene, antikörper und konjugate für ketamin und dessen metaboliten
ATE205602T1 (de) Verfahren und gerät zum nachweis und zur quantifizierung von glukose in körperflüssigkeiten
ATE400813T1 (de) Tumormarker für frühes krebsstadium
DE69121844D1 (de) Immunotest für Cyclosporin
EP2302382A3 (de) Docetaxel Konjugaten und Immunogenen zur Verwendung in einem Immunassay
DE60042066D1 (de) Chimärische dr4 antikörper und ihre verwendung
HK1053700A1 (en) Method and kit for detecting, or determining, 3,4-methylenedioxymethamphetamine
HK1113199A1 (en) An immunoassay method and kit to leucomalachite green and malachite green
WO2003106649A3 (en) CONJUGATE TEST AND USES THEREOF
DE60207016D1 (de) Verfahren und Kit zur Quantifizierung von Beta-Laktam Penizillinen
AU2002311679A1 (en) A differential labelling method
WO2000023785A3 (en) Improvements in luminescence assays
DE3670632D1 (de) Histamin-derivate, immunogen-konjugate und dadurch induzierte antikoerper.
ATE312842T1 (de) Reduziertes cortisolkonjugat
DE60332479D1 (de) Holo-transcobalamin bindungspartner und ihre verwendung in cobalamintest
DE69922680D1 (de) Detektion und quantifikation von vancomycin in den biologischen flüssigkeiten
EP1148339A3 (de) Immunoassay für LSD und 2-Oxo-3-hydroxy-LSD
EP1312923A3 (de) Verfahren und Kit zum Nachweis, oder zum Quantifizieren von, Metaboliten von Fentanyl und Metaboliten von Fentanyl Analogen
DE50214566D1 (de) Bioanalytische Messverfahren zur Bestimmung von Katalasen und Peroxidasen, deren Konjugaten, Substraten, Aktivatoren, und Inhibitoren
ES2151491T3 (es) Reactivos y procedimientos de cuantificacion de la imipramina o de la desipramina en fluidos biologicos.
PT774119E (pt) Moleculas de suporte oligomericas com grupos marcadores e haptenos incorporados de modo selectivo
ATE128361T1 (de) Lektinkomplex, sowie verfahren und sonde zu dessen herstellung.
DE59706692D1 (de) Konjugat, geeignet zur bindung von substanzen
DE60200051D1 (de) 1,2-Dioxetanderivate, Lumineszenzreagenzien, Lumineszenzverfahren und Messmethoden